I spoke with the CEO of the National Blood Authority, Adjunct Professor Ms Adriana Platona. She confirmed that the Australian Government owned the Commonwealth Serum Laboratories before it was privatised. She also stated that the National Blood Authority was established in 2003.

I asked her what steps had been taken to ensure the safety of concentrates containing Factor VIII. I did not receive a satisfactory answer—rather, I was given an attempted history lesson. Ms Platona went on to explain that the National Blood Authority was created as a result of the negative issues experienced by recipients of blood products during the 1970s, 1980s, and 1990s. She said that an apology had been issued. I question whether an apology alone is enough to compensate victims who were infected with Hepatitis C and HIV?

Ms Platona stated that there have been no contaminated blood incidents since 2003. I suggested that the Commonwealth Government surely had legacy responsibilities, at which point the Deputy Secretary of the Department, Ms Penny Shakespeare, intervened. She said that these issues were primarily the responsibility of the States and Territories. I pointed out that in March 1953 the WHO recommended that dried plasma should be taken from small pools of 10–20 donors only, for safety reasons. Apparently, by the mid-1980s in Australia, plasma was mass-pooled from large numbers of donors, contrary to WHO recommendations. I asked why this had occurred – which had to be taken on notice.

I then asked whether it was considered an acceptable risk—of high probability—that haemophiliacs would contract Hepatitis Non-A, Non-B, and Hepatitis C during the 1970s, 1980s, and 1990s. Again, I did not receive a satisfactory. I asked whether adequate compensation would be paid to the victims, as has happened in the UK, but was dismissed, and then my session was cut short by the Chair.

I will continue to seek justice for the victims of this terrible blunder by the Commonwealth and their continued denial of responsibility.

— Senate Estimates | October 2025

Transcript

Senator ROBERTS: I’ve got several issues here that I’d like to discuss—National Blood Authority about tainted blood, the pelvic mesh, the Lyme disease, ATAGI following on from Professor Lawler’s comments. So I’ll start with National Blood Authority, please. Is Dr John Rowell here? No. A lot of people are plagued with tainted blood, a heavy burden. At CSL’s 2024 annual general meeting, Chair Brian McNamee stated that, prior to its privatisation, the Australian government was the owner, funder and regulator of the Commonwealth Serum Laboratories. Is that correct?  

Prof. Platona: The National Blood Authority was formed in 2003 as a statutory legislative agency. I’m very happy to answer questions about the National Blood Authority’s role and work since 2003.  

Senator ROBERTS: I’m wanting to know if you could confirm that before the Commonwealth Serum Laboratories was sold off to the public, the Australian government was the owner, funder and regulator of the Commonwealth Serum Laboratories.  

Prof. Platona: I believe that is correct, sir.  

Senator ROBERTS: What steps did the Australian government take to regulate the safety of the Factor VIII and IX concentrates manufactured by the Commonwealth Serum Laboratories in the seventies, eighties and nineties?  

Prof. Platona: As I said in the first statement, the National Blood Authority was formed in 2003. I’m happy to answer questions about the work of the agency since then. You are referring to matters that precede the formation of the National Blood Authority by several decades.  

Senator ROBERTS: Could you tell me—I know it was a long time ago, but a lot of people are severely suffering now. Whose responsibility was it at the time, Ms Platona—is it Professor?—  

Prof. Platona: Yes. Ms Platona is fine.  

Senator ROBERTS: to ensure the safety of the Factor VIII and XI concentrates? This has relevance to what you’re doing now.  

Prof. Platona: Indeed. The National Blood Authority was formed, as I said, as a result of some negatively affected people in the seventies, eighties and nineties. My predecessor provided a lot of context in response to your question in November 2024 on Hansard, as to the steps that led to the formation of the National Blood Authority, the apology, the formation of what is now the national Red Cross Lifeblood organisation, the apology that Red Cross Lifeblood made in 2014, and a number of actions by state and territory governments to deal with, really, the failings of the blood transfusion in the past. I do not want you to think at all that I don’t think about the lives of the people that Haemophilia Foundation, for example, is working to support—not at all. I’m the officer that has got the Public Service Medal for making the direct antiviral medicines available. Those hepatitis C treatments are now considered to be best practice and curative. So I do want to acknowledge the hard circumstances of the people affected by the disease.  

Senator ROBERTS: That’s good. Did you want to say any more on that?  

Prof. Platona: I’m keen to do a good job, Senator.  

Senator ROBERTS: How can you do a good job for people with tainted blood? It was the government’s responsibility.  

Prof. Platona: Since the organisation was formed in 2003, to date there has been no contaminated blood incident.  

Senator ROBERTS: Do you not have any legacy responsibilities from your predecessors? The Commonwealth government is responsible.  

Ms Shakespeare: Prior to 1991, the Commonwealth’s role was largely through providing funding to state and territory governments to operate blood services. States and territories regulated the blood supply system in Australia until, as Ms Platona has explained, the National Blood Authority was established in 2003, and it now provides that national coordination. I think we also had the Therapeutic Goods Act 1989. After that, there were changes to the way that blood was regulated as well. Before that, the regulation largely would have been occurring through state and territory governments.  

Senator ROBERTS: But it was overseen by the Commonwealth. Let’s go through the history, and correct me if I’m wrong, Ms Shakespeare. In March 1953, the World Health Organization released a report that recommended dried plasma should be prepared from small pools of no more than 10 to 20 donors. This was ignored, and, by the mid-1980s, factor concentrates were being manufactured using mass pooled plasma from thousands of donors, significantly increasing the risk of hepatitis and HIV. Why were these early recommendations ignored? You weren’t around then, but that was a federal responsibility.  

Ms Shakespeare: We can try and take on notice if there’s anything in the archives about what happened in the 1950s, but it is a little bit difficult for us to talk to you about what happened at that time.  

Senator ROBERTS: Could you take these on notice then, please. It was in the mid 1980s. Factor concentrates were being manufactured using mass pooled plasma from thousands of donors, which went against the prevailing wisdom. Could you find out, Ms Shakespeare—and I thank you for your attention—if it was considered an acceptable risk that there was a high probability of haemophiliacs using factor concentrates that would be infected with hepatitis Non-A, hepatitis Non-B, hepatitis C in the seventies, eighties and nineties?  

Ms Shakespeare: Senator, what I can tell you is that the first specific test for hepatitis C became available in late 1989. Australia was one of the first countries to commence using the test, in November 1989, with implementation completed by February 1990. Similarly, we were one of the first countries to introduce HIV patient screening in May 1985. When tests have become available to make sure that the blood supply was safe and could be monitored for those particular medical issues, we’ve implemented that as early as possible.  

Senator ROBERTS: I’m wondering how to help these people.  

Ms Shakespeare: I think Ms Platona has spoken about some of the assistance that has been provided, and I can go through some of the help that has been provided. There was a review of the blood arrangements in 2001 that was conducted by a former High Court judge. The recommendations from that review were provided to all Australian Health Ministers and led to the establishment of the National Blood Authority and the centralised coordinated arrangements we have to ensure a safe and adequate blood supply that we still have today. We have haemovigilance—  

Senator ROBERTS: Can I interrupt?  

Ms Shakespeare: Of course.  

Senator ROBERTS: That would assume that, prior to that, the blood wasn’t considered to be safe.  

Ms Shakespeare: Decisions will have been made based on the state and territory governments’ delivery of blood products about the introduction of testing when it became available, when those tests were developed. As I said, compared to other countries, Australia was one of the first adopters and introduced those tests at a very early stage. But we didn’t just stop there. We’ve been establishing arrangements to make sure that the blood products that we provide to people today are nationally coordinated, that we’ve got consistent arrangements and that we don’t have differences between regulation and provision in different states and territories. The national haemovigilance program for Australia has been developed. That’s a set of surveillance procedures covering the entire blood transfusion chain, from donation and processing of blood to their provision and transfusion to patients. We have monitoring, reporting, investigating and analysing of adverse events related to donation processing and transfusion, and development and implementation of recommendations to prevent the occurrence or reoccurrence of adverse events. So we’ve got a whole haemovigilance program that now operates that’s been developed and implemented through the National Blood Arrangements. For people that have acquired hepatitis C the direct-acting antivirals, which were listed on the PBS in 2016—at that time that was the largest single PBS listing that had ever been made. We have future-generation directantivirals that are now provided through the PBS. If I can give an example, in 2023-24, we had 9,167 scripts of a drug called glecaprevir and pibrentasvir, which is a current-generation treatment for hepatitis C at a cost to government of $161 million. In the same year, sofosbuvir and velpatasvir, another medicine to treat people with hepatitis C, had 10,953 scripts at a cost to government of $131 million. So we’re providing access to those treatments. Now that covers anybody with hepatitis C. It doesn’t matter how they acquired it, but it would certainly benefit those who acquired it through the blood system before the testing was available.  

Senator ROBERTS: For some of these people with tainted blood, their lives have been really shot. Perhaps you could look at the camera—and I’m not trying to put pressure on you, or Ms Platona, or the minister, but what do we do for these people? Where do they go for compensation? Britain compensated their people with tainted blood, long, long, long ago; they admitted it and got on with the job. How do these people recover? How do these people get compensation if they can’t? I know you’ve given a list of drugs. What do we do?  

Ms Shakespeare: Those are curative, in many cases, direct-acting antivirals, which will be of significant benefit to people with hepatitis C. I should also say that the Australian government contributes to the hepatitis C litigation settlement schemes, which were set up and are managed by the state governments for people that were infected through the blood supply system before we had the National Blood Authority established. That offers financial settlements for people who contracted hepatitis C between 1985 and 1991. So there has been compensation made available and the Australian government contributes to that.  

CHAIR: Senator Roberts, I’m going to have to share the call. We are tight on time.  

Senator ROBERTS: Thank you for your interest, Ms Shakespeare.  

Ms Shakespeare: You’re welcome.